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Abstract
Background: Point-of-care CD4 testing can provide immediate CD4 reporting at HIV-testing sites. This study
evaluated performance of capillary blood sampling using the point-of-care Pima™ CD4 device in representative
primary health care clinics doing HIV testing.
Methods: Prior to testing, prescribed capillary-sampling and instrument training was undertaken by suppliers
across all sites. Matching venous EDTA samples were drawn throughout for comparison to laboratory predicate
methodology (PLG/CD4). In Phase I, Pima™ cartridges were pipette-filled with EDTA venous blood in the
laboratory (N = 100). In Phase II (N = 77), Pima™ CD4 with capillary sampling was performed by a single operator
in a hospital-based antenatal clinic. During subsequent field testing, Pima™ CD4 with capillary sampling was
performed in primary health care clinics on HIV-positive patients by multiple attending nursing personnel in a rural
clinic (Phase-IIIA, N = 96) and an inner-city clinic (Phase-IIIB, N = 139).
Results: Pima™ CD4 compared favourably to predicate/CD4 when cartridges were pipette-filled with venous
blood (bias -17.3 ± STDev = 36.7 cells/mm
3; precision-to-predicate %CV < 6%). Decreased precision of Pima™ CD4
to predicate/CD4 (varying from 17.6 to 28.8%SIM CV; mean bias = 37.9 ± STDev = 179.5 cells/mm
3) was noted
during field testing in the hospital antenatal clinic. In the rural clinic field-studies, unacceptable precision-to-
predicate and positive bias was noted (mean 28.4%SIM CV; mean bias = +105.7 ± STDev = 225.4 cells/mm
3). With
additional proactive manufacturer support, reliable performance was noted in the subsequent inner-city clinic field
study where acceptable precision-to-predicate (11%SIM CV) and less bias of Pima™ to predicate was shown (BA
bias ~11 ± STDev = 69 cells/mm
3).
Conclusions: Variable precision of Pima™ to predicate CD4 across study sites was attributable to variable capillary
sampling. Poor precision was noted in the outlying primary health care clinic where the system is most likely to be
used. Stringent attention to capillary blood collection technique is therefore imperative if technologies like Pima™
are used with capillary sampling at the POC. Pima™ CD4 analysis with venous blood was shown to be
reproducible, but testing at the point of care exposes operators to biohazard risk related to uncapping vacutainer
samples and pipetting of blood, and is best placed in smaller laboratories using established principles of Good
Clinical Laboratory Practice. The development of capillary sampling quality control methods that assure reliable
CD4 counts at the point of care are awaited.
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CD4 lymphocyte counts are used in HIV-positive
patients for initiation of antiretroviral therapy (ART), to
direct empiric treatments of suspected opportunistic
infection [1,2] and to identify patients failing therapy in
resource-poor settings [3]. In South Africa during 2010,
the national Department of Health embarked on a wide-
spread voluntary HIV counselling and testing (HCT)
initiative to drastically extend its national HIV/AIDS
ART programme across the country: almost 12 million
people were tested (18% of these HIV positive) in 12
months [4]. The South African National Health Labora-
tory Service (SA-NHLS) [5] currently supports an exten-
sive network of CD4 laboratories [6] to service this
increased need for testing across the country.
Easy to use, accessible and simplified technologies for
CD4 cell count testing at the point of care (POC) have
long been anticipated. Provision of an ideal, fully acces-
sible and decentralized near-patient CD4 count method
[7,8], which is also rapid, reliable, robust and affordable,
has nevertheless remained a challenge. Despite reserva-
tions of pathology testing at the POC [9,10], the prevail-
ing notion remains that provision of CD4 counts in the
context of voluntary counselling of patients for HIV/
AIDS could improve enrolment of eligible HIV-positive
patients onto ART programmes [11-15].
The Pima™ CD4 Analyser (Alere, South Africa),
described elsewhere [11,16], is a light, portable POC
CD4 instrument proposed for such near-patient CD4
testing. The aim of this study is to report on the out-
comes of the performance of the Pima™ CD4 analyser
in adults using either venous blood samples in the
laboratory or capillary blood sampling in typical South
African primary health HCT clinics where such technol-
ogy may be used, and compare performance of the
Pima™ against laboratory-based, state-of-the-art flow
cytometric predicate CD4 methodology [6,17].
Methods
Study description: phases of testing
This prospective validation of the Pima™ POC CD4
analyser (Alere: http://www.alere.com) was coordinated
through the SA-NHLS Charlotte Maxeke Johannesburg
Academic Hospital (CMJAH) CD4 reference laboratory,
located in Johannesburg, South Africa, and performed
according to the “Standards for Reporting of Diagnostics
Accuracy” (STARD) [18]. Ethics approval for this study
was obtained through the University of the Witwaters-
rand (protocol #M10116). Pima™ CD4 testing was per-
formed in adult patients only.
Phase I was designed to assess baseline inherent accu-
racy and precision of the instrument in a controlled
laboratory environment. During this phase of testing,
Pima™ cartridges were pipette-filled with a fixed
volume (20 mm
3)o fw e l l - m i x e dv e n o u sK 3EDTA anti-
coagulated blood taken from consecutive samples sent
for routine predicate CD4 testing (< 24 hours old, N =
100) at the SA-NHLS CMJAH laboratory.
In Phase II (N = 91), the impact of Pima™ testing
using manufacturer-prescribed capillary blood sampling
was evaluated in the same hospital (CMJAH) at the
antenatal HCT clinic using two of the Pima™ instru-
ments validated during Phase I testing (Pima #2 and
#3). To eliminate possible variation introduced with
varying sample age, Phase II was specifically designed to
facilitate laboratory testing on fresh samples (matched
venous EDTA samples for both predicate and Pima™
were tested within one to two hours of venesection).
Pima™ testing in the clinic was performed by a single
nursing sister, thereby avoiding variability potentially
introduced by multiple operators. A direct comparison
of Pima™ to Pima™ performance using matched
venous and capillary blood samples was also performed
(N = 77).
In Phase III,t h eP i m a ™ system was “field” tested.
This phase included two parts. In Phase IIIA (N = 96),
testing was undertaken independently through a local
donor-funded group in two Limpopo province primary
health care HCT clinics (semi-rural, less resourced),
where finger-prick sampling was routinely performed for
other pathology testing (typically HIV rapid testing).
Here, the Pima™ testing was performed by multiple
operators attending their respective patients; this is an
important perspective to assess performance in typical
HCT testing environments. Matching K3EDTA samples
were drawn simultaneously by phlebotomy staff and the
samples referred for comparative predicate CD4 testing
at the nearest SA-NHLS CD4 laboratory.
In Phase IIIB (N = 139), the Pima™ system was tested
in an inner-city primary health care HCT clinic in
Johannesburg. Testing was performed by two nursing
attendants. Matching K3EDTA samples were also drawn
simultaneously by phlebotomy staff and the samples
sent for comparative predicate CD4 methodology testing
at the nearby SA-NHLS Reference CMJAH CD4 labora-
tory. In this last phase of evaluation, following less
favourable outcomes noted in Phase II and IIIA field
testing, additional manufacturer-driven training and
support was given to operators to assess whether a
proactive approach to manufacturer support could
improve field performance seen in Phase IIIA.
The same lancet (Sarstedt Safety Lancet, 1.5 mm
Blade/1.6 mm depth, designated as “lancet 1”, n = 87)
was used for capillary sampling across all clinical phases
of testing. In the last sub-study (Phase IIIB), it was
tested alongside a different lancet (Carelet Blue Safety
Lancet/1.5 mm Blade/2.00 mm depth, designated “lancet
2”, n = 52) to assess whether lancet type had
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the previous clinical phases.
Testing of samples
Across the clinic sites and in the SA-NHLS CMJAH
laboratory respectively, Pima™ operator training for
either nursing personnel (Phases II and III) or dedicated
study scientists (Phase I) was undertaken by the suppli-
ers prior to commencing testing, according to methods
defined by the manufacturer. Reporting of either Pima™
or predicate CD4 results was blinded in the clinics and
the NHLS laboratories respectively. All patients who
had signed consent to participate in the study were
recruited on a first-come, first-serve basis for Phases II
and III of this study. Error codes and other instrument
error logs were noted by operators to establish the over-
all error rate of each instrument used (Tables 1, 2, 3).
Panleucogated (PLG) CD4 testing, the predicate meth-
odology of the SA-NHLS, described elsewhere [6,17],
w a su s e da st h er e f e r e n c es t a n d a r dt h r o u g h o u tt h i s
study. All PLG CD4 testing was performed by SA-NHLS
technologists working in the routine diagnostic service,
according to Good Clinical Laboratory Practice (GCLP)
and the Standard Operating Procedures of the SA-
NHLS [5].
Quality control
Daily Pima™ analyser quality control (QC) was per-
formed with manufacturer-supplied, reusable, bead-filled
cartridges with pre-defined counts (high and low con-
trols) before commencing daily testing. This QC was
performed for the duration of the study prior to sample
testing, both in the laboratory (during Phases I and II)
and on all analysers used in the field (Phases II and III).
Accuracy and precision of predicate PLG/CD4 testing
in both SA-NHLS laboratories was established by daily
monitoring of instrument stability (FlowCheck™,B e c k -
man Coulter, Miami, Fl), through further method and
system performance verification (Immunotrol™,B e c k -
man Coulter, Miami, Fl) [19,20], as well as ongoing con-
tinuous intra-sample quality bead-rate monitoring
[6,21]. The CMJAH SA-NHLS CD4 laboratory partici-
pates in the CD4/AFREQAS [22] and the UK NEQAS
[23], while the district SA-NHLS laboratory participates
in the CD4/AFREQAS. Both laboratories are South Afri-
can National Accreditation Service [24] accredited.
Process verification of Pima™ testing
Also, during Phase I, additional process verification con-
trols, “Normal” and “Low” Immunotrol™ (BC, Miami,
FL), were tested daily for nine consecutive days on the
Pima™ instruments in the laboratory (Figure 1). For
this analysis, 20 mm
3 of stabilized whole blood material
(Immunotrol™, Beckman Coulter, Miami, FL) was
manually pipetted into separate Pima™ cartridges (Fig-
ure 1) and analyzed individually on each instrument.
External quality assessment of Pima™ and predicate CD4
testing
Specifically assembled panels of archived SA-NHLS CD4
AFREQAS [22] stabilised blood samples were used to
further verify accuracy and precision of SA-NHLS predi-
cate testing, as well as being tested across four Pima™
instruments tested in the laboratory during Phase I (Fig-
ure 2A). In the Phase IIIA field study (Figure 2B), simi-
lar extended panels were used for external quality
assessment of the three field Pima™ instruments, as
well as the SA-NHLS laboratory performing comparative
predicate testing.
Table 1 Laboratory Pima™ testing using venous blood
Phase I
EDTA venous blood
Pima #1 Pima #2 Pima #3 Pima #4 All
Pima DATA
N 53 61 59 58 100**
Range of CD4 counts* 2-1297 4-1217 5-1190 7-972 4.5-1235
Mean CD4 count* 349 334 354 317 318
%Similarity to Predicate
(%SIM Mean ± SD)
99.26 ± 5.34 99.15 ± 5.35 99.64 ± 6.42 97.17 ± 5.01 98.17 ± 4.57
%SIM CV
# 5.38% 5.40% 6.44% 5.16% 4.66%
BA Bias* ± 1 STDev
(PIMA - PLG)
(95% CI of bias mean)
-14.38 ± 37.9
(-23.8 to -3.9)
-11.05 ± 42.4
(-21.9 to 0.19)
-13.6 ± 53.3
(-27.5 to 0.22)
-22.6 ± 40.3
(-33.2 to -12.0)
-17.3 ± 36.7
(-24.0 to -10.03)
BA 95% LOA* -88.7 to 59.9 -94.1 to 72.1 -118.2 to 90.8 -101.6 to 56.4 -89.4 to 54.7
Statistical analyses across four Pima™ analysers tested in the laboratory during Phase 1 using a fixed 20 mm
3 volume of manually pipetted EDTA venous blood
and compared against predicate flow cytometry (PLG/CD4). All values, with the exception of N, refer to CD4 cell counts in cells/mm
3. BA = Bland-Altman
statistical analysis. LOA = limits of agreement. #Precision of Pima™ to Predicate method expressed as %SIM CV.
*cells/mm
3
**The average Pima/CD4 value was used for comparison to predicate CD4 where more than two simultaneous Pima values were obtained.
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method were compared with the pooled global mean
CD4 results obtained through participation of all users
of the respective trials [25] to establish retrospective
external quality assessment. A standard deviation index
(SDI) or z-score value was calculated for each trial sam-
ple tested, with acceptable limits expected at between -2
and +2 SDI per result. Performance was represented in
modified radar plots as previously described [22,25] for
ease of comparison between instruments in Phase I or
sites during Phase IIIa.
Statistical analysis
All statistical analyses and graphic display of data were
generated with GraphPad Prism™ Software Version
5.03. Basic statistics, including minimum, maximum,
median and mean values, standard deviation (STDev)
and percentage coefficient of variation (%CV) for respec-
tive data sets were calculated where applicable. Absolute
CD4 results from both predicate (PLG/CD4) and by
Pima™ were compared using the % Similarity (%SIM)
model [26] with the derived %CV of the %SIM used as a
measurement of precision-to-predicate. All %SIM values
Table 2 Hospital antenatal Pima™ field testing using capillary blood
Phase II Laboratory Pima™ vs. Predicate Clinic Pima™ vs. Predicate
Venous EDTA blood Capillary blood
*Pima #1 *Pima #4 *Mean
Pima #1 and #4
Pima #3 Pima #2 All values
N 91 91 91 43 34 77
Range of CD4 counts* 32 - 1186 23 - 1299 28 - 1243 28 - 1092 50 - 1056 28 - 1092
Mean CD4 count*(median) 385.6
(341.0)
399.8
(357.0)
392.7
(347.0)
335.0
(405.0)
350.2
(290.0)
380.8
(329.0)
%Similarity to Predicate
(%SIM Mean ± SD)
96.9%
± 7.89
98.3%
± 7.05
97.6%
± 6.5
98.6%
± 28.45
96.1%
± 16.8
98.7
± 23.02
%SIM CV
# 8.1% 7.2% 6.7% 28.8% 17.6% 23.3
BA bias* ± 1 STDev
(PIMA - PLG)
(95% CI of bias mean)
-26.6 ± 73.3
(-41.9 to -11.4)
-12.4 ± 68.1
(-26.6 to 1.8)
-19.6 ± 66.1
(-33.3 to -5.8)
-31.79 ± 213.1
(-97.4 to 33.8)
-45.5 ± 127.7
(-90.1 to -1.0)
-37.9 ± 179.5
(-78.3 to 2.87)
BA 95% LOA* -170.4 to 117.1 -145.8 to 121.0 -149.1 to 110.0 -147.4 to 385.9 -295.8 to 204.6 -389.1 to 309.8
Statistical analysis of Pima™ analysers field-tested in a hospital-based antenatal HCT clinic (N = 77) and in the laboratory (N = 91) during Phase II testing versus
predicate reporting. A direct comparison of Pima performance using matched venous vs. capillary blood samples is shown. All values, with the exception of N,
refer to CD4 cell counts in cells/mm
3. BA = Bland-Altman statistical analysis. LOA = limits of agreement. #Precision of Pima™ to Predicate method expressed as
%SIM CV.
*cells/mm
3
Table 3 Primary health care clinic field testing using capillary blood
PHASE III Rural clinic Pima™ (3 sites)
versus Predicate (Phase IIIA)
Inner-city clinic Pima™ (1 site)
versus Predicate (Phase IIIB)
PREDICATE Pima™ PREDICATE Pima™
Lancet 1
(Sarsedt)
PREDICATE Pima™
Lancet 2
(Caralet Blue)
N 96 96 87 87 52 52
Range of CD4 counts* 2 - 1871 31 - 2747 2 - 1604 1 - 1358 3 - 966 2 - 968
Mean CD4 count*(median) 617.5
(492.0)
719.4
(677.5)
350
(302.0)
359.0
(305.0)
268.4
(255.5)
257.2
(238.0)
% Similarity to Predicate
(%SIM Mean ± SD)
114.8% ± 32.6 101.4% ± 10.1 98.6% ± 11.2
%SIM CV
# 28.4%CV 10.0% 11.3%
BA bias* ± 1 STDev
(PIMA - PLG)
(95% CI of bias mean)
+105.7 ± 225.4
(60.1 to 151.4)
+8.9 ± 112.3
(-14.9 to 32.8)
-11.2 ± 69.3
(-30.5 to 8.1)
BA 95% LOA* -336.0 to 547.0 -211.1 to 229.0 -147.0 to 124.6
Statistical analysis of for Pima™ analysers field-tested in Phases IIIA and IIIB across two rural (N = 96) and one inner-city HCT clinic (N = 139), respectively, versus
predicate reporting. All values, with the exception of N, refer to CD4 cell counts in cells/mm
3. BA = Bland Altman statistical analysis. LOA = limits of agreement.
#Precision of Pima™ to Predicate method expressed as %SIM CV.
*cells/mm
3
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the CD4 result was < 100 cells/mm
3.I nt h e% S I M
model, method agreement is adequate where %SIM cal-
culated values fall between 95% and 105% and where
precision of test-method to predicate-method (%SIM
CV) is shown to be < 8%. Bland-Altman analyses [27],
with the bias (difference) defined as [Test minus Predi-
cate], were used to indicate bias and agreement between
technologies. Where indicated, to assess true differences
at lower CD4 counts without the influence of higher
CD4 counts in the data sets, data was grouped into two
categories: CD4 count of < 350 cells/mm
3 and therefore
eligible for treatment by World Health Organization
guidelines [28]) and CD4 count of > 350 cells/mm
3,t h e
level of patients who are generally ineligible for treat-
ment in the SA programme (except in the presence of
AIDS-defining opportunistic illnesses).
The non-parametric t-test and Mann-Whitney test
were used to establish possible significance of differ-
ences between predicate and Pima™ CD4 results. Com-
parison of two or more groups of data was performed
using one-way ANOVA for non-parametric tests, with
Kruskall Wallis testing used to establish a p value and
Pred Pima 1 Pima 2 Pima 3 Pima 4
0
100
200
300
400
500 P<0.05
P<0.05
6.6% 5.6% 4.4% 5.2% 0.57%
6.4% 8.1% 10.0% 10.0% 2.14%
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Figure 1 Daily quality control.F i g u r et os h o we x c e l l e n t
reproducibility using stabilized whole blood quality control material,
i.e., IM “normal” and IM “low” across both predicate (PLG/CD4) and
four Pima™ analysers during laboratory testing in Phase I.
Statistically significant differences (Student’s t-test, p < 0.05)
between predicate and Pima™ CD4 counts, shown in the figure,
reflect tight precision-to-predicate demonstrated in the %SIM
analysis. No statistical differences were, however, noted between
individual Pima™ analysers when testing either IM normal or IM
low material (one-way ANOVA, p > 0.05). Performance using
external quality control material is shown in Figure 2.
(A) 
Phase I.  AFREQAS stabilised whole blood, pipette-filled Pima cartridges 
(Bi) 
Phase IIIA.  AFREQAS stabilised whole blood, pipette-filled Pima cartridges 
(Bii) 
(Biv)  (Biii) 
Pima #2  Pima #3 
Pima #4  Pima #1 
Figure 2 External quality assessment using retrospective AFREQAS samples. Figure to show performance of Pima™ analysers using panels
of retrospective SA-NHLS AFREQAS stabilized blood samples to establish external quality assessment of testing. In (A) performance of four
Pima™ analysers - Pima™ analysers #2 and #3 were subsequently used for field testing in Phase II and in (B) during Phase III, the SA-NHLS
Predicate (SA-NHLS Polokwane using PLG/CD4 - performance is noted together with performance of three independent Pima™ analysers field
tested using pipette-filled cartridges on site. See details in text. Red circles define acceptable limits of ± 2 SDI and the green circle represents
ideal performance (SDI = 0). Actual performance of the respective laboratory/clinic is shown in blue.
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nificant differences between groups, where applicable.
Results
Pima™ daily quality control
During Phase I, documented bead-cartridge quality con-
trol analysis over time (26-32 days) reflected excellent
instrument precision (%CVs of < 2.5%) irrespective of
instrument used (Pima #1-4). Review of the bead QC
revealed cartridge-bead “low"/"high” counts of 152/995,
150/961, 149/989 and 221/828 beads/mm
3 for Pima
instruments #1-4, respectively, with longitudinal low/
high QC reproducibility (CV%) of 1.4%/1.6%, 1.9%/0.6%,
2.1%/0.7% and 1.9%/1.1% noted. Control cartridge
within-instrument precision testing, performed at least
once for each instrument in a replicate set of 10 bead
analyses during Phase 1, yielded similar results to the
longitudinal reproducibility we have described, with
low/high bead QC %CVs noted at 2% or less. Similar
QC bead cartridge precision was shown throughout
other phases of testing (data not shown). Of note, speci-
fically in the rural field clinic HCT during Phase IIIA,
Pima™ instrument bead precision was excellent and
noted at 2.88%CV and 1.81%CV for “low” and “high”
bead control cartridges, respectively (suggesting accepta-
ble instrument performance in the context of the poorer
sampling testing performance subsequently noted at this
site).
Process-verification QC of both the predicate metho-
dology, as well as individual Pima™ analysis (Figure 1)
was also performed during Phase I using the commer-
cially available stabilised blood product, Immunotrol™
(IM, Beckman Coulter, Miami, FL). IM “normal” and
IM “low” materials (manufacturer range 422 ± 165 and
142 ± 18 cells/mm
3 respectively) were analysed for nine
consecutive days on both the MC-XL flow and across
four Pima™ instruments (Figure 1). For IM “normal”
and IM “low” material, this analysis revealed excellent
day-to-day precision of predicate CD4 testing (PLG-
CD4 MC-XL) with %CV 0.5% and CV 2.0% noted,
respectively. Acceptable precision was seen across four
Pima™ analysers, with average %CV of 6.2% and 9.1%
noted, respectively (Figure 1).
Bland-Altman bias analysis confirmed the negative
bias noted in the %SIM analysis, i.e., -47.8 ± STDev =
23.5 cells/mm
3 (IM “normal”) and -13.3 ± STDev = 11.7
cells/mm
3 (IM “low”). In other words, the predicate
CD4 counts read higher than Pima™,b u tw e r es t i l l
within the defined limits of the IM product package
insert. Further testing using a panel of 10 retrospective
AFREQAS (stabilised) blood samples performed in
Phase I revealed similar overall under-reading by
Pima™, with all Pima™ results falling within acceptable
2SDI limits (Figure 2A). Despite underestimation of
CD4 counts by Pima™ instruments when either stabi-
lised blood product was tested in comparison with pre-
dicate results (%SIM decreased between 92% and 95%),
differences noted were relatively constant, as reflected
by the tight precision of similarity of Pima™ CD4 to
predicate methodology (%SIM CV < 5%). These differ-
ences were not regarded as clinically significant.
Phase I: evaluation of Pima™ performance using K3EDTA
venous blood
Results of Phase I testing with venous blood (N = 100)
is shown in Table 1. Overall, a consistent and very tight
negative bias with small variation around the bias was
noted (-17 ± STDev = 36.7 cells/mm
3 and Bland Altman
(BA) 95% limits of agreement of -89.4 to 54.7 cells/
mm
3). Excellent agreement between methods was noted
in the %SIM analysis with an average 98% ± STDev
4.6% (range 97.7% to 99.6%) and very tight precision-to-
predicate demonstrated (mean %SIM CV < 7%). During
this phase, between-instrument precision simultaneously
tested across two (N = 8), three (N = 25) or four
Pima™ analysers (N = 24) was excellent and showed no
statistically significance difference in CD4 counts
between Pima™ instruments (p > 0.05, one-way
ANOVA): between-analyser precision was calculated at
~9.4%CV across four instruments. There were no “no-
read” errors noted in the laboratory evaluation.
Phase II: impact of capillary blood sampling on
performance of Pima™ at the POC in a hospital based
antenatal clinic
A larger negative bias, with wider variation around this
bias, was documented between Pima™ CD4 and predi-
cate CD4 counts (Table 2, Figure 3B) in an antenatal
primary health care (PHC) clinic where a single operator
performed the testing using capillary sampling. The %
SIM analysis (Figure 3B) confirmed loss of precision in
relation to that seen when venous blood was tested by
Pima (Figure 3A), with corresponding %SIM CV
decreasing to17.6% and 28.8% for each of the two
instruments used in the clinic, respectively (average cal-
culated 23.3CV%; see Table 2 and Figure 3B for details).
“No read” errors were noted in five of 48 (10.4%) and
nine of 43 (20.93%) samples tested on each of the
respective instruments used.
Also during Phase II, the impact of capillary blood
sampling on Pima performance was highlighted in a
direct comparison of Pima™ to Pima™ using matched
capillary and venous blood samples taken from the same
patient and tested at the same time. Poor precision (%
SIM CV = 26.5%) between the two sampling methods
was revealed (Figure 3C). As expected [29,30], the BA
analysis revealed a moderate mean bias of -18 cells/mm
3
between sampling methods. However, wide BA limits of
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differences, varying from -336.7 to 299.0 cells/mm
3.
Phase III: “field” testing
During Phase III, the Pima™ was “field” tested in a
semi-rural PHC clinic (termed Phase IIIA, where multi-
ple operators participated), followed by assessment in a
better-resourced inner-city clinic (termed “Phase IIIB”,
where only two operators performed testing). At the
rural site, of the 111 samples drawn, eight could not be
tested in the laboratory as the samples were clotted on
receipt and were excluded from the final analysis. A
further seven of the 111 (6.8%) samples did not have
matching Pima™ results due to “no read"/"invalid” CD4
readings recorded at the clinic sites (ethics clearance did
not allow for repeat capillary sampling to be performed).
In the final comparison of 96 matching CD4 results (see
Table 3 for details), Bland-Altman bias analysis revealed
an overall substantial, clinically significant difference to
predicate reporting (105.7 to ± 225.4 cells/mm
3)w i t h
very wide limits of agreement revealed (95% LOA -336.0
to +547.4 cells/mm
3).
A sub-analysis done within the 96 sample set to investi-
gate this bias in the CD4 count range less than 500 cells/
mm
3 (Figure 4A) or less than 350 cells/mm
3 (Figure 4B)
similarly revealed very wide mean BA bias of 102.3 ±
STDev = 199.6 and 131.4 ± STDev = 207.7 cells/mm
3,
respectively. Although counts were lower, a wider LOA
in the < 350 cells/mm
3 group revealed increasing error in
this clinically relevant CD4 range (Figure 4A and 4B).
Further analysis of the outlying results in this group to
assess possible misclassification of patients’ eligibility for
ART, revealed that 10 out of 32 patients would have
missed an opportunity for ART initiation if tested by
Pima™ o ns i t e ,w i t h1 6o f3 2r e c o r d i n gad i f f e r e n c eo f
Pima™ CD4 to predicate CD4 of > 30% (50.0% of
patients tested). Further, in those patients with CD4
counts of greater than 350 but less than 500 cells/mm
3,
23.5% (four of 17) had significantly higher CD4 counts by
Pima™ testing than by predicate methodology and
would ultimately have missed the opportunity for therapy
intervention. A further eight of 17 (41.7%) patients were
shown to have POC Pima™ CD4 results with > 30% dif-
ference to predicate testing. Percentage similarity analysis
of the full data confirmed these findings, with Pima™
reading higher than predicate (114.8 ± 32.6%) and %SIM
CV reflecting the wide variation of Pima reporting rela-
tive to predicate reporting (average 28.4%CV).
The bead cartridge quality control performed on the
Pima™ instruments used at these sites however
reflected acceptable baseline instrument reproducibility
( n=1 0 ,%C Vo f2 . 8 %a n d% C Vo f1 . 8 %f o rl o wa n d
normal bead-cartridge analyses, respectively), confirming
0 500 1000 1500
-1000
-500
0
500
1000 Bias
SD of bias
95% Limits of Agreement
From
To
-19.55
66.09
-149.1
110.0
Average
D
i
f
f
e
r
e
n
c
e
 
(
P
i
m
a
/
E
D
T
A
 
-
 
P
r
e
d
i
c
a
t
e
)
0 500 1000 1500
-1000
-500
0
500
1000 Bias
SD of bias
95% Limits of Agreement
From
To
-37.87
179.5
-389.7
313.9
Average
D
i
f
f
e
r
e
n
c
e
 
(
P
i
m
a
/
C
B
 
-
 
P
r
e
d
i
c
a
t
e
)
0 500 1000 1500
-1000
-500
0
500
1000 Bias
SD of bias
95% Limits of Agreement
From
To
-18.81
162.2
-336.7
299.0
Average
D
i
f
f
e
r
e
n
c
e
 
(
P
i
m
a
/
C
B
 
-
 
P
i
m
a
/
 
E
D
T
A
)
(A)  
(B)  
(C)  
Capillary vs. Venous blood 
Pima to Predicate 
%SIM CV = 23.3% 
Venous vs. Capillary blood 
Pima to Pima  
%SIM CV = 26.5% 
Venous  vs. venous blood 
Pima to Predicate 
%SIM CV =6.7% 
N=96 
N=77 
N=77 
Figure 3 Pima™ performance with venous and capillary blood
sampling. In (A), Predicate and Pima™ are both tested using
venous EDTA blood, revealing excellent method agreement and
small, clinically insignificant bias between systems. In (B), decreasing
precision of Pima™ precision-to-predicate CD4 is noted where
capillary blood sampling is used. The mean bias is within clinically
acceptable limits; however, the variation noted around the mean
bias is poor, with unacceptably wide LOA noted (range > 600 cells/
mm
3). In (C), further decreasing precision-to-predicate is revealed
with even higher %SIM %CV noted in a direct Pima™ to Pima™
comparison of capillary versus venous blood. Although overall BA
bias between sampling methods is clinically insignificant, the
variation of this bias (reflected in the 95% LOA) is unacceptably
wide, confirming the poor %SIM CV of 26.5%. Bland-Altman values
shown above are cells/mm
3. CB = capillary blood.
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Page 7 of 13operator influence. Testing of the AFREQAS panel per-
formed after the initial field study, where AFREQAS QC
material was manually pipetted into cartridges by opera-
tors, served to confirm inherent reliability of the Pima™
instruments used at these clinics; a few outlying results
noted on this analysis across the three instruments used
in the field clinics (Figure 2Bii, iii and 2iv) reflecting
inexperience with pipetting technique. Importantly, test-
ing of the same 25-sample AFREQAS panel by the
regional SA-NHLS laboratory demonstrated acceptable
and reliable external quality assessment performance of
the NHLS laboratory that performed the comparative
predicate technology (Figure 2Bi).
D u r i n gt h el a s tp h a s eo ft e s t i n g( P h a s eI I I B ) ,t h ep e r -
formance of the Pima™ instrument was evaluated in an
inner-city PHC HCT clinic (Table 3, Figure 4C and 4D).
“No read” errors were reported in 14 of a total of 153
samples tested (final N = 139). In striking contrast to
the Phase IIIA findings, the %SIM analysis showed con-
siderably less bias and tighter LOA variance, irrespective
of whether lancet 1 (N = 87, 101.4% ± STDev = 10.1%)
or lancet 2 (N = 52, 98.6% ± STDev = 11.2%) was used.
Adequate precision-to-predicate method was also
demonstrated (%SIM CV noted at 10.0% and 11.3% for
lancets “1” and “2”, respectively).
Discussion
The study was undertaken to assess the performance of
the Pima™ POC CD4 instrument in a primary health
care HCT clinic environment using manufacturer-pre-
scribed capillary blood sampling. The study involved
testing on adult patients only and did not include chil-
dren younger than 18. In this regard, the Pima™ analy-
ser only reports absolute CD4 counts and cannot be
used where CD4% of lymphocyte values are required
used for pediatric clinical assessment.
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Page 8 of 13Overall, Pima™ performance varied markedly between
field study sites and was shown to depend on the quality
of the capillary blood sampling (overall field study %SIM
CVs varied from 11.3 to 28.3%, see Tables 2, 3 and Fig-
ures 3, 4.). The Bland-Altman analysis (LOA) revealed
wide variation to predicate counts, varying from accep-
table limits (BA LOA, -147.0 to 124.6 cells/mm
3 in the
inner-city study site) to unacceptable limits in a rural
primary health care environment where multiple attend-
ing nursing staff, trained and practiced in finger-prick
sampling for rapid HIV testing performed both capillary
blood sampling and Pima™ analysis (BA LOA, -336.0 to
547.0 cells/mm
3). The %SIM CV confirmed this varying
precision of Pima™ to predicate counting, varying from
acceptable levels (10.0%CV to 11.3%CV) to unacceptable
levels (varying from 17.6%CV to 28.8%CV) in field
clinics. This finding was consistent across sub-studies
performed (phases II and III), irrespective of whether a
single user (Phase II) or multiple users (Phase III) had
performed the testing (detail in Tables 2 and 3). Similar
variation has noted in peer-reviewed literature (also see
additional file 1).
Similar variation and poor precision was also noted
when matched Pima™ to Pima™ evaluation of venous
versus capillary samples were tested, further confirming
the negative impact of (poor) capillary blood sampling
on Pima™ performance (Figure 3C). These results are
contrasted by excellent Pima™ performance noted in a
controlled laboratory setting [31] when venous blood
was used for Pima™ testing (%SIM CV 4.7%, see Tables
1, 2 and Figure 3A).
The Pima™ field data from the rural primary health
care setting is of particular concern as it reflects a sce-
nario where the Pima™ analyser is most likely to be
used in the context of HIV and PHC clinics. Several
aspects warrant discussion in this context. First, pro-
blems related to capillary sampling are likely to be uni-
versal and not unique to Pima™ analysis: any small
device that uses capillary sampling is likely to be
affected by such sampling error. Proactive and continu-
ous supplier training did result in an improvement of
performance (Phase IIIB/inner-city clinic) but still less
than that noted with venous blood. Intensive and
ongoing training has been recommended [16,32,33] to
improve performance in this context. Such an approach
m a yn o t ,h o w e v e r ,b es u s t a i n a b l ei nt h el o n g e rt e r m
across a multitude of sites, especially if instruments are
used in PHC facilities situated in less accessible, rural
areas. Substantial human resources will be needed going
forward to provide continuous training and supervision
to ensure proper capillary sampling at the POC, espe-
cially where multiple operators may be required to use
the system, as noted in our rural field study, further
complicated by problems of high staff turnover [34].
Several factors may have played a role in the variable
testing precision noted here and in other related studies
[16,33,35]. Some non-operator dependent biological fac-
tors may have possibly affected capillary sampling
include viz. possible rapid clotting of capillary blood
[36,37]: Pima™ reporting was acceptable in at least one
site, suggesting that clotting of samples is unlikely to
have caused poor precision. Sampling type per se is
excluded: capillary blood parameter values are not
expected to vary from values in venous blood [38], cer-
tainly not in relation to haematological counts [29] and
after discarding the first drop of blood [30].
Differences to predicate counts (variability) noted here
are therefore most likely attributable to differences in
quality of sampling. In this context, the terminology
("finger-prick”) itself is confusing. Capillary blood sam-
pling is different from typical “finger-prick” bleeding.
Lack of attention to testing protocols and inconsistent
or absent quality control has been previously reported
during HCT at the POC with the much simpler “rapid
HIV test”, which uses true finger-prick sampling [39].
The sampling required for Pima™ CD4 testing is differ-
ent and more akin to a classic haematological “bleeding
time”. It is therefore possible that lack of insight into
the difference between finger-prick and capillary bleed-
ing methods contributed to variability noted here, espe-
cially in those clinics where operators claim familiarity
with “finger-prick” techniques used for HIV rapid test-
ing. Reinforcement about differences between finger-
prick and capillary sampling is therefore vital: the
importance of absolute strict adherence to prescribed
manufacturer methods of sampling to ensure adequate
precision and accuracy of the Pima™ CD4 reporting at
the POC cannot therefore be overemphasised.
Some inadequate cartridge filling, related to poor sam-
pling, may have also contributed to the poorer perfor-
mance noted in the rural clinics. Higher percentages (up
to 23%) of “no read” readings have been similarly noted
elsewhere [40]. Lancet type as a reason for poorer per-
formance was excluded: no difference in performance
was noted when the recommended Sarstedt/lancet 1 or
the alternative Caralet Blue/lancet 2 was used.
The second point pertains to use of quality control
material and the separate need for a quality control
method to ensure quality of the capillary bleed.
Although we (Figures 1 and 2), and others [35], have
shown that process control or external quality assess-
ment material can be used in the Pima™ analyser, such
use only monitors inherent instrument performance and
does not provide quality control of the most variable
aspect of near-patient testing, the capillary bleed, which
is crucial to ensure individual sample accuracy. Cur-
rently, this elusive and variable aspect of POC testing is
the biggest challenge to ensuring quality CD4 counts at
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Page 9 of 13the POC. Research to develop a system for monitoring
quality control of capillary sampling by operators is
therefore desperately needed, especially in a primary
health care environment where operator handling can
negatively impact upon Pima™ results (or any other
instrument at the POC that uses capillary sampling).
Third, the best use of the technology in its current
format, bearing in mind the current limitations of poor
capillary sampling quality revealed in our field studies,
pertains to the idea that POC CD4 technologies, used in
conjunction with HCT, will identify patients eligible for
treatment [7,13,41]. We have shown variable precision,
which causes either under- or in the case of our rural
PHC field study, significant over-reading by Pima™ (BA
bias was noted at +105.7 cells/mm
3 and confirmed by
the %SIM model of 114.8 ± 32.6%). In our study,
patients who would have therefore missed the opportu-
nity for ART at a 350 CD4 cell/mm
3 cut-off (where
Pima™ read falsely higher than predicate CD4)
accounted for about 31% of participants in the rural
PHC study. Here, more than 50% of patients tested
showed a more than 30% difference (negative or positive
bias) to predicate count. Other published studies have
reported less numbers of patients misclassified (lost) for
ART: 6.7-14% [16], 5.2% [35] or 17% [33].
In this context, local studies reveal very small and
slow rises of CD4 counts after commencement of ART
(only reaching median levels around 350 cells/mm
3
levels at three years post ART, [42]). Monitoring of such
small patient responses to ART may therefore be both
difficult and unreliable if such CD4 technologies with
limited precision were also used to follow up patients’
response to ART. This translates to mean that Pima™
POC CD4 testing or any POC system with reduced pre-
cision-to-predicate is best used for screening only, and
in conjunction with better quality controlled, more
robust, laboratory-based CD4 testing for patient follow
up. This will ensure that overall, long-term, follow-up
patient care is not compromised, especially if CD4
counts are used to predict treatment failure [3,43].
T h ea l t e r n a t i v ei nt h eP H CH C Tc o n t e x tw h e r eC D 4
testing is to be used at the POC is to consider venous
draw-based Pima™ testing. Manipulation of venous
blood samples does, however, unfortunately expose the
operator to biohazard risks associated with working with
blood samples and may not be a practical option in all
HCT clinics. Operators would require, at minimum, a
dedicated area for sample testing and some training in
GCLP [44] and need to be trained to uncap and recap
vacutainer tubes and pipette venous blood into Pima™
cartridges. Such a within-clinic testing facility is possible
[41,45], but requires dedicated staff to run the service:
such testing is probably more appropriately placed in a
smaller or mini-laboratory where such safety
precautions can be implemented as routine practice.
Despite the obvious disadvantage of testing venous
blood at the POC, patients may prefer a venous blood
draw.
CD4 counting is not the only pathology testing [33,46]
required for staging and assessing eligibility of patients
for ART. At minimum, a haemoglobin value, along with
AST and ALT testing, cholesterol and urea and electro-
lyte testing, are required to assess eligibility before ART
can be commenced. Here, repeated finger-pricks
required to test each parameter individually on separate
machines are likely to be uncomfortable and not readily
accepted by patients: the idea of a single venous draw to
perform multiple POC pathology testing (for testing in a
PHC mini-lab or referral to a local nearby laboratory)
may still be a more practical and acceptable option to
patients, especially if they are required to return to the
clinics anyway for adherence counselling before com-
mencing ART [41].
The fourth point relates to costs of providing CD4
counts at the POC. Systems like Pima™ are likely to
cost significantly more than conventional flow cytometry
testing. Reagents/lancets for Pima™ testing are esti-
mated at about US$10 per test, excluding other so-
called hidden costs including quality control bead con-
sumables, instrument maintenance and associated nur-
sing personnel labour costs. Pima™ analysers and the
required printers are quoted separately at more than
$6000. In contrast, certainly in South Africa, predicate
laboratory-based testing is charged in an all-encompass-
ing fee for service of about $7-8 per test: this is fully
inclusive of instrument placement and maintenance,
reagents, labour and laboratory overheads. In such a
scenario, POC CD4 testing could potentially therefore
more than double current costs of conventional
lab-based testing, depending on how widely it is
implemented.
Recent studies show only modest increases in the pro-
portion of patients who had received CD4 results at the
POC who are subsequently successfully enrolled onto
ART (from 12% to 22% [47] or 33% versus 47% [41]:
loss to follow up remains high despite these early inter-
ventions. Bearing this in mind, and considering that
resources may be better spent on improving existing
laboratory infrastructure to improve all pathology ser-
vices across a national health service, a tiered approach
to service implementation [8] is envisaged through the
SA-NHLS National Priority Programme. This would
range from high-volume, centralised and consolidated
laboratory testing [6] through local district laboratory
servicing to fully decentralised POC testing in areas
with very limited or no laboratory servicing [8], inte-
grated with all other pathology services. This model,
based on mapping existing primary health and HCT
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potentially extends services to many more national
laboratories to provide CD4 and other relevant and
appropriate pathology servicing required for patient sta-
ging for ART. This approach maximises analyser service
delivery and most effectively uses current funds and
resources to ensure overall equitable access to CD4 and
other pathology testing, irrespective of geographic loca-
tion or clinic resource.
Conclusions
In this study we have shown that, during field testing,
the quality of capillary blood sampling negatively
impacted on the precision and accuracy of the Pima™
point-of-care CD4 analyser. Capillary sampling therefore
demands absolute diligence and stringency of sampling
technique. Ongoing dedicated training as well as imple-
mentation of systems for monitoring and evaluation of
testing is strongly recommended. Additional, properly
controlled cost-benefit field studies [46], independent
field studies and financial modelling studies to ensure
best and efficient use of resources are, however, still
needed. A true POC CD4 test for initiation of ART in
an ideal dipstick version, which is both accurate and
reliable, as well as cheap, is still eagerly awaited [48,49].
Additional material
Additional file 1: Review of relevant peer-reviewed literature of
related Pima™™ studies and other comparative technologies. The
table contains data taken from recent peer-reviewed publications where
Pima™™ is compared to various predicate or alternative CD4
methodologies. Here, although in many instances mean bias between
compared technologies is relatively small and acceptable, it is important
to point out that these bias values are frequently not quoted in the
context of actual method agreement. Here, attention is specifically drawn
to the ranges of the ‘limits of agreement’ of the BA mean bias, which
reflect the actual variation of differences noted between the
technologies compared and give an idea of the precision of the
methodology or new analyser tested in relation to that of the reference
predicate method. For ease of comparison between studies, results have
therefore been categorised into three groups according to the range of
the Bland Altman limits of agreement. i.e., where the range is narrow
and acceptable, and falls below 200 cells/mm
3 (highlighted in blue),
those studies that reveal greater than 200 cells/mm
3 but less than 300
cells/mm
3 limits (highlighted in grey), and those studies that show very
wide limits of agreement, greater than 300 cells/mm
3 (highlighted in
red) and where corresponding %SIM %CV is shown to exceed 10%). Of
note especially, is that the laboratory-based cluster within the group that
show narrow BA limits of agreement, i.e., limits of agreement less than
200 cells/mm
3.
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